4.7 Article

Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results

期刊

JOURNAL OF CLINICAL MEDICINE
卷 12, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/jcm12010291

关键词

magnetic resonance-guided radiotherapy (MRgRT); adrenal gland metastases (AGM); stereotactic body radiotherapy (SBRT); adaptive radiotherapy

向作者/读者索取更多资源

Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). This study reviewed data from 12 consecutive patients treated with MRgRT for AGM and assessed the treatment's impact on target volume coverage, organ protection, local control, and overall survival. The results showed improved dosimetric quality and good tolerance of the treatment, with high rates of local control and overall survival. Longer follow-up is needed to evaluate late toxicities and clinical outcomes.
Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC), and overall survival (OS). The majority of patients were oligometastatic (58.3%), with 6 right AGM, 5 left AGM and 1 left and right AGM. The prescribed dose was 35 to 50 Gy in 3 to 5 fractions. The median PTV V95% on the initial plan was 95.74%. The median V95% of the PTVoptimized (PTVopt) on the initial plan was 95.26%. Thirty-eight (69%) fractions were adapted. The PTV coverage was significantly improved for adapted plans compared to predicted plans (median PTV V95% increased from 89.85% to 91.17%, p = 0.0478). The plan adaptation also significantly reduced Dmax for the stomach and small intestine. The treatment was well tolerated with no grade > 2 toxicities. With a median follow-up of 15.5 months, the 1-year LC and OS rate were 100% and 91.7%. Six patients (50%) presented a metastatic progression, and one patient (8.3%) died of metastatic evolution during the follow-up. Adaptation of the treatment plan improved the overall dosimetric quality of MRI-guided radiotherapy. A longer follow-up is required to assess late toxicities and clinical results.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据